"The trial, known as ACTIV-1 Immune Modulators, will determine if the therapeutics are able to restore balance to an overactive immune system."
Hyderabad: Hyderabad-based generic pharmaceuticals company Hetero launched its ‘patient compliant pack’ of Favivir 800/200 for the treatment of mild-to-moderate symptomatic Covid-19 patients in India. Favivir...
“This partnership is timely and in line with our strategic growth plans for the company."
Hyderabad-based company signs an exclusive agreement to make intermediates and bulk drugs for intravenous administered drug
Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalised with severe symptoms. Redyx is available in a strength of 100 mg vial.
Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.
Aim to ensure adequate supply of antivirals and steroids to treat Covid-19 patients
The mobile Covid-19 testing buses along with ambulances and trained personnel will visit the containment zones
Remdesivir is the first drug that Canada has authorised for the treatment of Covid-19, according to a press release on Tuesday from Health Canada, Xinhua reported.
Rachakonda CP requested citizens to complaints against those selling medicines and oxygen cylinders for higher rates on Dial-100 or Rachakonda WhatsApp No- 9490617111
The drug is approved for the treatment of suspected or laboratory confirmed incidences of Covid-19 in adults and children hospitalised with severe presentations of the disease
The seven persons were procuring generic versions of Remdesivir and Cipremi injections and selling the same at higher prices to Covid-19 patients and making huge money, police said.
A resident of Golconda, Sikander Ali Khan, 29, had complained to the police on Tuesday that he purchased three Remdesivir injections from one medical store near the NIMS hospital for his relative who is taking treatment for Covid-19.
This is an important finding that requires confirmation in prospective clinical trials, Gilead said on Friday about the results presented at the virtual COVID-19 conference as part of the 23rd International AIDS Conference
Gilead Sciences extended a voluntary non-exclusive license to Cipla in May to manufacture and market Cipla's generic version of remedisvir called Cipremi.
One of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar.
Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies, said, “In the light of increasing Covid-19 cases in India, the approval of ‘Covifor’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes.